Abstract
Bristol-Myers Squibb (BMS) is a research-based, worldwide pharmaceutical and
related health care products company. BMS was founded in 1989, and currently
operates through three main business divisions: Pharmaceuticals, Nutritionals
and Other Health Care. Within Pharmaceuticals, BMS' key areas of interest are
cardiovascular and metabolic disorders, virology, oncology, neuroscience and
immunology.
Since the merger to form the company in 1989, BMS has consistently been in the
top ten research-based pharmaceutical companies in terms of pharmaceutical
sales. However, in 2006, BMS reported its third consecutive year of revenue
loss, which looked to threaten this position. The company is going through a
transitional period, whereby many older products have seen considerable
declines in sales due to generic competition whilst newer products begin to
establish themselves in the market place. In fiscal 2007, BMS once again
returned to revenue growth.
BMS' is looking to refresh its product portfolio, adopting a strategy of
increased R&D investment despite decreased income. To this end, BMS' research
to sales ratio has increased from 12.2 per cent in 2003, to 17.4 per cent in
2008. Higher levels of expenditure have reaped dividends for the company with
five new products launched between 2005 and 2006. Orencia, Sprycel, Emsam,
Atripla and Baraclude signify the first stages of BMS' new direction and
profile.
There are also several established products in the portfolio which will help
drive BMS' pharmaceutical sales in the future. Avapro continues to benefit
from co-development and co-marketing with sanofi-aventis and, along with
Plavix, is the main focus of their collaboration. BMS is a world leader in
virology, with the Sustiva franchise (which now includes Atripla) and Reyataz
forecast to be leading competitors in this field for some time. The company is
also heavily involved in projects to provide HIV/AIDS treatment on a worldwide
scale, most notably in sub-Saharan Africa where there is the highest level of
unmet medical need. Within neuroscience, Abilify continues to sell well,
whilst in oncology, Erbitux has been launched and is being investigated in a
variety of oncology conditions. This versatility should ensure strong sales
growth.
This new strategic analysis report Bristol-Myers Squibb: Pipeline -
Products - Performance - Potential, provides a complete and critical
review of the company and includes unique and independent assessments and
forecasts of key products. Buyers of the web edition receive online access for
one year via an easy-to-use interface with fast navigation and a full text
search facility. All formats are the same price.
| 
View Cart
